All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

FDA grants Breakthrough Therapy Designation to acalabrutinib for adult patients with CLL

Aug 15, 2019

Bookmark this article

On the 14th of August 2019 the US Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) for acalabrutinib as a monotherapy treatment for adult patients with chronic lymphocytic leukaemia (CLL).

Acalabrutinib, is an inhibitor of Bruton tyrosine kinase (BTK) involved in pathways regulating B-cell proliferation, chemotaxis, and adhesion. The decision was based on positive results from the interim analyses of two phase III clinical trials, ELEVATE-TN and ASCEND.

The drug was previously granted accelerated approval for the treatment of adult patients with R/R mantle cell lymphoma (MCL). Acalabrutinib is also currently being evaluated, as a monotherapy and in combination, in 26 clinical trials in indications including CLL, MCL, diffuse large B-cell lymphoma, Waldenström macroglobulinaemia, follicular lymphoma, and multiple myeloma.

Expert Opinion

  1. AstraZeneca. Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia. Press release 14th August 2019. [Accessed  August 15 2019]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

Which treatment do you select for patients with follicular lymphoma after multiple relapses?
0 votes - 6 days left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox